Renaissance Capital logo

Karuna Therapeutics Priced, Nasdaq: KRTX

Phase 2 biotech developing therapies for schizophrenia and other CNS disorders.

Industry: Health Care

Latest Trade: $66.54 0.00 (0.0%)

First Day Return: +25.1%

Return from IPO: +315.9%

Industry: Health Care

We are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. Our pipeline is built on the broad therapeutic potential of our lead product candidate, KarXT, an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues. KarXT is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. We are currently conducting a Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia and expect preliminary results in late 2019. We also plan to initiate clinical trials of KarXT to evaluate its potential therapeutic benefit in other CNS disorders, including psychosis in Alzheimer’s disease, or AD, as well as pain. We have assembled a team whose members have extensive expertise in the research, development and commercialization of numerous CNS agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and AD, including the role of muscarinic receptors in their potential treatment. We plan to leverage this expertise to develop a pipeline of product candidates targeting a broad range of psychiatric and neurological conditions.
more less
IPO News for Karuna Therapeutics
more
IPO Data
IPO File Date 05/31/2019
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 5.6
Deal Size ($mm) $89
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/27/2019
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 5.6
Deal Size ($mm) $89
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Boston, MA
Founded 2009
Employees 16
Website www.karunatx.com